www.astrazeneca.com
Eight regulatory actions, one dominant sponsor: FDA approvals, May 17–22, 2026
AstraZeneca secured three wins in a single five-day window — Enhertu's dual early breast cancer labels, Baxfendy's first-in-class aldosterone synthase inhibitor, and Fasenra's rare HES expansion — plus a first interchangeable golimumab biosimilar, Trimbow's U.S. debut, a bladder cancer companion diagnostic, a robotic shoulder 510(k), and an Impella safety alert.
This edition covers a compressed five-day window (May 17–22), following last week's Saturday publication. Most drug actions carry formal FDA dates of May 14–15 but were publicly announced during the current window. AstraZeneca accounts for three of the five drug decisions — Enhertu's two early breast cancer labels, Baxfendy's first-in-class hypertension approval, and Fasenra's hypereosinophilic syndrome expansion — spanning oncology, cardiovascular medicine, and immunology in a single five-day span. The device half of the ledger is thinner: a bladder cancer companion diagnostic, a robotics clearance expansion, and an FDA safety warning.
All actions at a glance
| Date | Name | Sponsor | Indication / use | Type |
|---|---|---|---|---|
| May 15 | Enhertu (T-DXd) — neoadjuvant | Daiichi Sankyo / AstraZeneca | HER2+ Stage II/III early breast cancer, pre-surgery | Label expansion (sBLA, Standard Review) |
| May 15 | Enhertu (T-DXd) — adjuvant | Daiichi Sankyo / AstraZeneca | HER2+ early breast cancer with residual disease after neoadjuvant therapy | Label expansion (sBLA, Priority Review + BTD) |
| May 15 | Baxfendy (baxdrostat) | AstraZeneca | Uncontrolled hypertension, add-on to existing therapy | Novel NME (first-in-class) |
| May 15 | Immgolis / Immgolis Intri (golimumab-sldi) | Accord BioPharma / Bio-Thera | RA (SC+IV); UC (SC only) | Biosimilar (interchangeable) |
| May 14 | Fasenra (benralizumab) | AstraZeneca | Hypereosinophilic syndrome (HES), adults and children ≥12 | Label expansion |
| May 14 | Trimbow (BDP/FF/G) | Chiesi USA | Asthma maintenance, adults | New combination (first US SITT) |
| May 18 | Signatera CDx (Natera) | Natera | Companion diagnostic — MIBC post-cystectomy, guiding Tecentriq | CDx approval |
| May 21 | Impella AIC (Abiomed / J&J) | Abiomed | Intravascular circulatory support controller | FDA safety alert — software error, death reported |
| May 22 | Rosa Shoulder System (Zimmer Biomet) | Zimmer Biomet | Robotic-assisted shoulder surgery, expanded indication | 510(k) expanded clearance |
Note: The Datroway (Dato-DXd) TNBC approval (May 22) is flagged under "What to watch."
Drug approvals and label expansions
Enhertu (T-DXd) — two simultaneous labels in early HER2-positive breast cancer
FDA date: May 15, 2026 1
Drug: Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd) — an antibody-drug conjugate (ADC) pairing a HER2-directed antibody with a topoisomerase I inhibitor payload via a cleavable linker. The high drug-to-antibody ratio (~8) enables a bystander killing effect on neighboring cells. Prior approvals covered HER2-positive and HER2-low metastatic breast cancer, HER2+ gastric cancer, and HER2-mutant non-small cell lung cancer. These two labels mark T-DXd's first entry into the curative-intent early-stage setting.
Sponsors: Daiichi Sankyo, Inc. and AstraZeneca, under a March 2019 global collaboration. Both companies co-develop and co-commercialize Enhertu. U.S. sales are recognized by Daiichi Sankyo.
Companion diagnostics co-approved: PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody and VENTANA HER2 Dual ISH DNA Probe Cocktail (both Ventana/Roche), used to confirm HER2-positive (IHC 3+ or ISH+) status. Both indications were reviewed under FDA Project Orbis with seven international agencies. 1
Indication 1 — Neoadjuvant: T-DXd (5.4 mg/kg every 3 weeks, 4 cycles) followed by THP (taxane + trastuzumab + pertuzumab, 4 cycles), for adults with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer before surgery. Regulatory path: sBLA, Standard Review.
Pivotal trial — DESTINY-Breast11 (NCT05113251), n=927, three-arm, open-label 1:
| Endpoint | T-DXd → THP | ddAC → THP (control) | p-value |
|---|---|---|---|
| Pathological complete response (pCR) | 67.3% (95% CI: 61.9–72.4%) | 56.3% (95% CI: 50.6–61.8%) | 0.003 |
| Absolute improvement | +11.2 percentage points (95% CI: 3.9–18.3) | — | — |
ILD/pneumonitis rate in the T-DXd → THP arm: 4.4% — substantially lower than the 12–15% rate observed in metastatic settings. 2
Indication 2 — Adjuvant: T-DXd (5.4 mg/kg every 3 weeks, 14 cycles) for adults with HER2-positive breast cancer who have residual invasive disease after neoadjuvant trastuzumab (± pertuzumab) plus taxane-based therapy. This replaces T-DM1 (Kadcyla, the standard since 2019) in this setting. Regulatory path: sBLA, Priority Review + Breakthrough Therapy Designation. 1
Pivotal trial — DESTINY-Breast05 (NCT04622319), n=1,635, randomized 1:1 T-DXd vs. T-DM1 1:
| Endpoint | T-DXd | T-DM1 | HR (95% CI) | p-value |
|---|---|---|---|---|
| 3-year invasive disease-free survival (IDFS) | 92.4% | 83.7% | 0.47 (0.34–0.66) | <0.0001 |
| Risk reduction vs. T-DM1 | 53% | — | — | — |
T-DXd events: 51 of 818 patients (6.2%). T-DM1 events: 102 of 817 patients (12.5%). 1
Safety note (adjuvant): ILD/pneumonitis occurred in 9.6% of T-DXd patients vs. 1.6% on T-DM1, including 7 Grade 3 events and 2 Grade 5 (fatal) events. 1 NCCN Guidelines have already incorporated T-DXd as a Category 1 recommendation for this adjuvant setting.
"HER2-positive early disease is considered highly curable, however up to one in four patients still experience disease recurrence, underscoring the need for new options in this setting. These approvals mark an important step forward, expanding the possibility of cure to more patients for the first time in many years."— Dave Fredrickson, EVP Oncology Haematology, AstraZeneca 1
"I don't see a downside in using a more effective therapy that's less toxic for our patients."— Shanu Modi, MD, Memorial Sloan Kettering Cancer Center 3
Commercial context: The addressable adjuvant population in the U.S. — HER2+ early breast cancer patients with residual disease after neoadjuvant therapy — is approximately 15,000 patients annually (based on ~64,000 annual HER2+ early-stage diagnoses and roughly one-quarter experiencing incomplete response to neoadjuvant therapy). 1 These approvals triggered a $155 million milestone payment from AstraZeneca to Daiichi Sankyo. 1 Enhertu's combined global sales for Q1 2026 were approximately $1.42 billion, up 31% year-over-year. 4
Loading link preview…
Baxfendy (baxdrostat) — first-in-class aldosterone synthase inhibitor for hypertension
FDA date: May 15, 2026; announced publicly May 18 5
Drug: Baxfendy (baxdrostat) — a small-molecule, oral, once-daily aldosterone synthase inhibitor (ASI). Baxdrostat selectively inhibits CYP11B2 (aldosterone synthase) with approximately 100:1 selectivity over CYP11B1 (cortisol synthase), plasma half-life >30 hours. At doses of 0.5–5 mg, it reduces plasma aldosterone by 51–73% without affecting cortisol. 5 This selectivity addresses a longstanding limitation of existing aldosterone-pathway drugs: ACE inhibitors and ARBs can trigger aldosterone escape after 6–12 months, while mineralocorticoid receptor (MR) antagonists such as spironolactone block both aldosterone and cortisol at the receptor level and paradoxically raise circulating aldosterone. 6
Sponsor: AstraZeneca, which acquired baxdrostat through its $1.8 billion purchase of CinCor Pharma in February 2023.
Indication: Add-on to other antihypertensive medicines for adults with uncontrolled hypertension — specifically patients whose blood pressure remains inadequately controlled despite existing therapy. The label is not restricted to resistant hypertension. Recommended dose: 2 mg once daily; 1 mg for patients at elevated risk of hyperkalemia or hyponatremia. No REMS required. 7
Pivotal trial — BaxHTN (NCT06034743), n=796, randomized 1:1:1 to baxdrostat 2 mg, 1 mg, or placebo, added to existing therapy 5:
| Arm | Absolute SBP reduction (12 weeks) | Placebo-corrected reduction | p-value |
|---|---|---|---|
| Baxdrostat 2 mg | 15.7 mmHg (95% CI: 13.7–17.6) | 9.8 mmHg (95% CI: 7.0–12.6) | <0.001 |
| Baxdrostat 1 mg | 14.5 mmHg (95% CI: 12.5–16.5) | 8.7 mmHg (95% CI: 5.8–11.5) | <0.001 |
| Placebo | 5.8 mmHg | — | — |
Epidemiological data indicate a 10 mmHg reduction in systolic blood pressure is associated with roughly a 20% lower risk of serious cardiovascular events. 5 Results were consistent across the uncontrolled and resistant hypertension subgroups. An additional Phase 3 trial (Bax24, NCT06168409) demonstrated statistically significant reductions in 24-hour ambulatory blood pressure, published in The Lancet (March 2026). 6
Key safety: The most common adverse reactions (≥2%, exceeding placebo by ≥1%) are hyperkalemia (6.6% at 1 mg; 10.2% at 2 mg), hypotension (2.1% / 3.6%), hyponatremia (2.1% / 3.2%), dizziness (3.0% / 2.9%), and muscle spasms (1.8% / 2.9%). 7 Serum potassium and sodium should be checked before treatment and monitored during therapy, with increased frequency in patients aged ≥65, with diabetes, CKD, or on potassium-raising medications.
"We have been waiting for an innovative medication like Baxfendy for hypertension for many years. Its novel way of lowering blood pressure has the potential to transform clinical practice by targeting a root cause of persistently uncontrolled hypertension."— Dr. Bryan Williams, Chair of Medicine, University College London; BaxHTN principal investigator 5
Commercial context: AstraZeneca projects peak annual sales exceeding $5 billion for Baxfendy. 8 Approximately 23 million U.S. patients have uncontrolled hypertension despite taking two or more antihypertensive medications. 5 The previous novel-mechanism oral antihypertensive to reach U.S. approval was Tryvio (aprocitentan, Idorsia), a dual endothelin receptor antagonist cleared in March 2024. Baxfendy's nearest ASI-class competitor is lorundrostat (Mineralys Therapeutics), which has a PDUFA date in December 2026. Lorundrostat's Launch-HTN Phase 3 trial showed a placebo-corrected systolic reduction of 9.1 mmHg at 6 weeks (50 mg arm). 6 Baxfendy's first-mover position in a large and underserved population gives it a meaningful launch advantage, but pricing and payer access decisions — not yet publicly disclosed — will shape how quickly it converts that advantage.
Loading link preview…
Fasenra (benralizumab) — expanded to hypereosinophilic syndrome
FDA date: May 14, 2026 9
Drug: Fasenra (benralizumab) — an IL-5 receptor alpha–directed, cytolytic monoclonal antibody that depletes eosinophils and basophils. Prior U.S. approvals: severe eosinophilic asthma (SEA) and eosinophilic granulomatosis with polyangiitis (EGPA). Developed by AstraZeneca with rights licensed from BioWa, Inc. (a Kyowa Kirin subsidiary).
New indication: Hypereosinophilic syndrome (HES) in adults and children aged 12 and older, where no identifiable non-hematologic secondary cause is confirmed. HES is a rare group of disorders defined by persistently elevated eosinophil counts and eosinophil-mediated organ damage; if untreated, it can be fatal. Estimated U.S. prevalence: 0.3–6.3 per 100,000. Recommended dose: 30 mg subcutaneous injection every 4 weeks; available as a single-dose prefilled syringe and autoinjector. 9
Pivotal trial — NATRON (Phase 3, n=133, randomized 1:1, 24 weeks) 9:
| Endpoint | Fasenra | Placebo | Result |
|---|---|---|---|
| First HES flare risk reduction | — | — | 65% lower (HR 0.35; 95% CI: 0.18–0.69; P=0.0024) |
| Patients experiencing ≥1 flare | 22% | 45% | OR 0.31 (95% CI: 0.14–0.69; P=0.003) |
| Annualized flare rate | 0.41/year | 1.23/year | Rate ratio 0.34 (P=0.0008) |
| PROMIS fatigue score improvement | −8.6 | −3.9 | P=0.0017 |
| Patients requiring OCS dose increase | 18% | 42% | — |
Results were published in Nature Medicine (online March 31, 2026). Most common adverse reactions (≥5%, above placebo): headache, hypersensitivity reactions including urticaria, and flu-like symptoms. 10
"People living with hypereosinophilic syndrome struggle every single day. Debilitating fatigue, risk of organ damage, skin manifestations, and other symptoms adversely impact patients' lives, making it difficult to maintain normal daily activities, including work."— Mary Jo Strobel, Executive Director, American Partnership for Eosinophilic Disorders 9
Commercial context: HES is an orphan-scale indication with limited treatment options — no biologic had been approved for HES before this decision. The approval extends Fasenra's eosinophil-targeting franchise into a third indication, adding a rare disease label that typically commands premium pricing and favorable reimbursement.
Immgolis / Immgolis Intri (golimumab-sldi) — first interchangeable golimumab biosimilars
FDA date: May 15, 2026 11
Drug: Immgolis (golimumab-sldi, subcutaneous) and Immgolis Intri (golimumab-sldi, intravenous) — the first interchangeable biosimilars to Simponi (golimumab, Janssen Biotech) and Simponi Aria (golimumab IV). Golimumab is a human anti-TNF-alpha monoclonal antibody.
Approved indications:
- Immgolis (SC): moderately to severely active rheumatoid arthritis (RA, combined with methotrexate) and moderately to severely active ulcerative colitis (UC). Available as 50 mg/0.5 mL and 100 mg/mL single-dose prefilled syringes.
- Immgolis Intri (IV): RA only (combined with methotrexate). Available as 50 mg/4 mL single-dose vials.
- Neither product is approved for psoriatic arthritis (PsA), ankylosing spondylitis (AS), or polyarticular juvenile idiopathic arthritis (pJIA). 11
Sponsors: Bio-Thera Solutions (Guangzhou) developed the products and manages supply; Accord BioPharma, Inc. (U.S. specialty pharma subsidiary of Intas Pharmaceuticals, Newark, NJ) holds exclusive U.S. commercialization rights. Accord plans a Q4 2026 U.S. launch.
Litigation risk: Janssen Biotech (Johnson & Johnson) filed a BPCIA patent suit against Accord BioPharma and Bio-Thera in the U.S. District Court for the District of Delaware on March 3, 2026, and applied for a preliminary injunction on May 6, 2026. 12 Accord and Bio-Thera must respond by June 8, 2026. If the court grants the injunction, the Q4 2026 launch timeline will face a material delay.
Trimbow (BDP/FF/G) — first single-inhaler triple therapy approved for asthma in the U.S.
FDA date: May 14, 2026 13
Drug: Trimbow (beclomethasone dipropionate 86 or 172 mcg / formoterol fumarate 4.9 mcg / glycopyrrolate 10.6 mcg) — a fixed-dose combination of an inhaled corticosteroid (ICS, BDP), a long-acting beta agonist (LABA, FF), and a long-acting muscarinic antagonist (LAMA, glycopyrrolate), delivered via a pressurized metered-dose inhaler (pMDI). Taken twice daily, 2 puffs per dose.
Sponsor: Chiesi USA, Inc. (Cary, NC) — the U.S. subsidiary of Chiesi Farmaceutici S.p.A. (Parma, Italy, private). Trimbow has been approved in approximately 50 countries including the EU, UK, and China. This is Chiesi USA's first FDA-approved product.
Indication: Maintenance treatment of asthma in adults. Not indicated for COPD; not for acute symptom relief; not for pediatric patients. Dosing: 2 inhalations twice daily (maximum 4 inhalations per day). 13
Pivotal trials: TRIMARAN and TRIGGER (two Phase 3 trials, combined n>2,200) compared Trimbow vs. BDP/FF (ICS/LABA dual therapy) and demonstrated statistically significant improvements in lung function with a comparable safety profile. 14 Trimbow's extrafine-particle formulation is designed to reach small airways — approximately 50–91% of asthma patients across severity grades have small airway dysfunction (SAD). 13
Competitive positioning: Three triple-combination inhalers were already on the U.S. market before Trimbow — Trelegy Ellipta (fluticasone/umeclidinium/vilanterol, GSK/Innoviva) and Breztri Aerosphere (budesonide/glycopyrrolate/formoterol, AstraZeneca) are both COPD-first; Trelegy also carries an asthma indication. Trimbow enters as an asthma-only single-inhaler triple therapy with extrafine particle differentiation.
Device actions (May 17–22)
Signatera CDx (Natera) — companion diagnostic for muscle-invasive bladder cancer
Date: May 18, 2026 15
Device: Signatera CDx (Natera, Inc., Austin, TX) — a tumor-informed circulating tumor DNA (ctDNA) liquid biopsy assay. Natera sequences the patient's tumor tissue to identify 16 personalized somatic variants, then tracks those specific variants in serial blood samples.
Indication as CDx: Identifies muscle-invasive bladder cancer (MIBC) patients with circulating tumor DNA molecular residual disease (ctDNA MRD) after radical cystectomy — selecting who should receive Tecentriq (atezolizumab) adjuvant immunotherapy. This CDx approval is the device-side component of last week's Tecentriq adjuvant MIBC approval (see prior edition).
Clinical basis: In the IMvigor011 trial, patients with Signatera-positive results (ctDNA MRD-positive) who received Tecentriq achieved a median disease-free survival of 9.9 months vs. 4.8 months on placebo. Patients with ctDNA-negative status had a 2-year disease-free survival of 88%. Nearly half of MIBC patients tested negative during the surveillance window and could safely defer treatment. 15
Commercial context: One full year of Tecentriq adjuvant therapy costs approximately $196,000, according to Natera's clinical diagnostics president Solomon Moshkevich on the company's Q1 earnings call. 15 Identifying and sparing the ~50% of patients who remain ctDNA-negative represents meaningful cost containment as well as patient benefit. This is the first CDx approval enabling MRD-guided treatment in bladder cancer.
Loading link preview…
Rosa Shoulder System (Zimmer Biomet) — 510(k) expanded clearance
Date: May 22, 2026 16
Device: Rosa Shoulder System (Zimmer Biomet Holdings, Inc., NYSE: ZBH) — a robotic-assisted surgery platform for shoulder procedures. The Rosa Shoulder received its initial FDA clearance in 2024. This 510(k) expanded clearance covers an advanced version of the system.
Context: Full procedural and technical details were not available prior to publication, as the MassDevice article hosting primary detail was not accessible for verification. 16 The clearance extends Zimmer Biomet's Rosa robotics franchise — which already covers total knee arthroplasty (Rosa Knee, cleared 2019) and total hip arthroplasty (Rosa Hip) — into the shoulder segment.
Abiomed Impella AIC — FDA safety alert citing software error and reported deaths
Date: May 21, 2026 17
Device: Automated Impella Controller (AIC) — the electronic controller unit for the Impella family of intravascular heart pumps (Abiomed, Inc., a Johnson & Johnson company, Danvers, MA). The Impella line is the market-leading percutaneous circulatory support device used in high-risk cardiac procedures and cardiogenic shock.
Action: The FDA issued an early warning notification to healthcare providers about a software error in the AIC that poses a potential high-risk problem. At least one death has been reported in connection with the identified issue. This is a safety alert, not a recall or clearance; healthcare providers should follow FDA guidance on device management and patient monitoring protocols. 17
Full technical details of the software defect and FDA's specific mitigation instructions were not confirmed from verifiable primary sources prior to publication.
Market and investor context
AstraZeneca secured three distinct regulatory wins across three therapeutic areas in a single week — Enhertu (oncology), Baxfendy (cardiovascular), and Fasenra (rare immunology). Together these represent significant milestones toward AstraZeneca's stated goal of reaching $80 billion in annual revenue by 2030. Despite the positive regulatory news, AZN stock (Nasdaq: AZN) showed a "buy the rumor, sell the news" pattern: the shares fell 1.8% on May 15 to $181.58 (from $184.96 the previous close), and were roughly flat on May 18. 18 Analyst consensus remains Strong Buy: 13 Buy ratings, 1 Hold, 1 Sell, with an average 12-month price target of $217.43. 18
The Immgolis / Immgolis Intri story is straightforward in regulatory terms — first interchangeable golimumab biosimilars, planned Q4 2026 launch — but the Janssen preliminary injunction application introduces meaningful binary event risk before launch. Investors in Accord BioPharma (private; parent company Intas Pharmaceuticals) and Bio-Thera Solutions should track the Delaware federal court's ruling on that injunction after June 8.
Natera's Signatera CDx approval is structurally important beyond the single bladder cancer indication. The MRD-guided treatment paradigm — test ctDNA, treat only those with residual disease — has been expected across multiple solid tumor types for several years. Each additional CDx approval strengthens the case for Signatera reimbursement across oncology programs and positions Natera at the center of precision oncology test ordering.
What to watch
Datroway (datopotamab deruxtecan-dlnk, Dato-DXd) — AstraZeneca and Daiichi Sankyo's separate TROP2-targeting ADC, distinct from Enhertu, received FDA approval for unresectable or metastatic triple-negative breast cancer (TNBC) first-line treatment on May 22, 2026. This approval was identified during research for this edition but was not fully covered in this run's research units. It will receive dedicated coverage in the next edition (May 23–30).
Cover image generated for editorial use.
References
- 1
- 2AstraZeneca US: ENHERTU approved for two new indications
astrazeneca-us.com
- 3
- 4Zacks via Yahoo Finance: AZN, Daiichi's Enhertu gets FDA nod
finance.yahoo.com
- 5
- 6
- 7
- 8
- 9AstraZeneca: Fasenra approved in U.S. for hypereosinophilic syndrome
astrazeneca-us.com
- 10Pulmonology Advisor: Fasenra receives FDA approval for hypereosinophilic syndrome
pulmonologyadvisor.com
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.